TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02747745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four risk areas reflecting the great needs of FCGs of PWDs
Description: The intervention involves home visits \& phone calls from the case manager to the dyads, and receiving telephone calls from FCGs. The case manager will target the prioritized risk from the 4 risk areas of FCG problems and healthy behaviors. The intervention mainly consists of needs assessment and nursing education on home environment modification and safety, behavioral management and communication skills; home-based cognitive stimulation on PWD with simple mathematical practice, patient preferred leisure activities and reminiscence by old time photos, stories and toys; brief consultation on 4 risk areas related to FCG stress; and case management to refer the dyads to the hospital-based dementia centers and community resources.
Study: NCT00175357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: The dose of the drug will be determined by a physician. The oral drug will be administered 1 dose per days, 7 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diamorphine hydrochloride
Description: The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
Study: NCT02010762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 25.000 IU oral drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo oral drops
Study: NCT04647604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven®
Description: A highly refined fish oil in an emulsion for infusion with purified egg phosphatides and glycerol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: intravenously administered 2 mL/kg/day
Study: NCT01955590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Description: 8-12 sessions of manualized metacognitive therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMDR
Description: 8-12 sessions of manualized EMDR

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: 8-12 sessions of treatment of usual
Study: NCT02695732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopy
Description: Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.
Study: NCT02597543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: For use in stress myocardial perfusion imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: For use in stress myocardial perfusion imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For use in both perfusion imaging and late gadolinium enhancement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For use in both perfusion imaging and late gadolinium enhancement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Cardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Cardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.
Study: NCT04686253

Intervention type: OTHER
Intervention: not appliable
Description: not appliable

Intervention type: OTHER
Intervention: not appliable
Description: not appliable

Intervention type: OTHER
Intervention: not appliable
Description: not appliable
Study: NCT03655106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Long IV 4.78 cm 20 g catheter
Description: Standard Long IV 4.78 cm 20 g catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-Long IV 6.35 cm 20 g catheter
Description: Ultra-Long IV 6.35 cm 20 g catheter
Study: NCT00508170

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.
Study: NCT01718639

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IQP-LH-101 tablet
Description: Oral medical device in the form of a chewable tablet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IQP-LH-101 liquid
Description: Oral medical device in the form of a liquid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02684682

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Frequency of mechanical control of plaque (12h)
Description: Performing oral hygiene 12 in 12 hours, with tooth brush and interdental device.
Study: NCT01791712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: On-line hemodiafiltration
Description: pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-flux Hemodialysis
Description: blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
Study: NCT02684682

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Frequency of mechanical control of plaque (24h)
Description: Performing oral hygiene 24 in 24 hours, , with tooth brush and interdental device.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Frequency of mechanical control of plaque (48h)
Description: Performing oral hygiene 48 in 48 hours, , with tooth brush and interdental device.
Study: NCT03377881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI/Fusion biopsies
Description: The intervention in the experimental arm is an MRI with targeted biopsies using fusion technique to prostate lesions. Repeat screening is offered after 2-6 years on an individualised basis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Systematic biopsies
Description: The intervention in the control arm is traditional systematic biopsies of the prostate.
Study: NCT04240938

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dacryocystorhinostomy
Description: Anastomosis between lacrimal sac and nasal cavity
Study: NCT01303978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421
Description: Single dose
Study: NCT02710201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Descriptive Social Norm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Descriptive-plus-Injunctive Social Norm
Study: NCT04281706

Intervention type: DRUG
Intervention: Etomidate vs Propofol as induction agent
Description: Patients undergoing cardiac surgery were induced with Etomidate according to the standard operating procedure for induction until October 1st, 2013, afterwards a new SOP with Propofol as primary induction agent was introduced. After a washout period of 3 months, Propofol was used as sole induction agent. The rest of the standard operating procedure remained the same.

Intervention type: DRUG
Intervention: Etomidate vs Propofol as induction agent
Description: Patients undergoing cardiac surgery were induced with Etomidate according to the standard operating procedure for induction until October 1st, 2013, afterwards a new SOP with Propofol as primary induction agent was introduced. After a washout period of 3 months, Propofol was used as sole induction agent. The rest of the standard operating procedure remained the same.
Study: NCT01935440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention & Testing
Description: 6 group sessions, 1 individual session, and 1 dyad session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevention & Testing Control
Description: 7 group sessions
Study: NCT02924948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon inflation
Description: EUS balloon inflation will be done before insertion through the subjects throat
Study: NCT00357448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox
Description: Given IP at 3 dose levels: 5mcg/kg of ONTAK, 15mcg/kg of ONTAK, or 25mcg/kg of ONTAK

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraperitoneal administration
Description: After completion of I.P. normal saline infusion, the I.P. catheter will be capped and patients will be turned/rotated for 1 hour to help facilitate I.P. bathing w/ONTAK; patients will be turned/rotated every 15 minutes in 4 different positions for a total of 1 hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study: NCT03220867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone: Xian Risperdal (test)
Description: Participants will receive 1\*1 mg tablet of Xian Risperdal under fasting or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone: Xian Risperdal (test)
Description: Participants will receive 1\*1 mg tablet of Xian Risperdal under fasting or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone: Gurabo Risperdal (reference)
Description: Participants will receive 1\*1 mg tablet of Gurabo Risperdal under fasting or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone: Gurabo Risperdal (reference)
Description: Participants will receive 1\*1 mg tablet of Gurabo Risperdal under fasting or fed condition.
Study: NCT01424722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices
Description: Algorithm for detecting ST changes that may be indicative of an acute coronary syndrome.
Study: NCT01485965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 100 mg, immediate release tablets, once daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 100 mg, immediate release tablets, once daily administration
Study: NCT03680898

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal swab collection
Description: Patient will provide a rectal swab by following hospital-provided instructions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rectal swab collection
Description: Patient will provide a rectal swab by following hospital-provided instructions.
Study: NCT04449484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI1341
Description: Intravenous infusion over 60 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion over 60 minutes
Study: NCT00864864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
Study: NCT03252470

Intervention type: PROCEDURE
Intervention: Laparoscopic Roux-en-y Gastric Bypass Surgery
Description: Laparoscopic Roux-en-y Gastric Bypass Surgery

Intervention type: PROCEDURE
Intervention: Laparoscopic Roux-en-y Gastric Bypass Surgery
Description: Laparoscopic Roux-en-y Gastric Bypass Surgery
Study: NCT01418157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: 125 mg twice daily until 4380 meters altitude

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily
Study: NCT02391064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive evaluation
Description: * Questionnaires for assessment of confounding factors~* Cognitive evaluation~* Walking tests and 9 Hole Peg Test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive evaluation
Description: * Questionnaires for assessment of confounding factors~* Cognitive evaluation~* Walking tests and 9 Hole Peg Test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Disability Status Scale (EDSS) score
Description: - EDSS score
Study: NCT01192646

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HBLSS
Description: Home Based life saving skills training will be done in the intervention cluster while in the control group no training

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: HBLSS
Description: Home Based life saving skills training will be done in the intervention cluster while in the control group no training
Study: NCT01307098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa 0.35 mg/kg
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa 1 mg/kg
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa 3 mg/kg
Description: Sebelipase alfa is a recombinant human lysosomal acid lipase.
Study: NCT00995410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA32540
Description: PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
Study: NCT02048865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Apixaban 2.5 mg tablets BID for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: placebo drug 2.5mg BID for 6 months
Study: NCT01453075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Valacyclovir 1.5 mg po bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo twice daily
Study: NCT00919308

Intervention type: OTHER
Intervention: Competency based simulation training
Description: Completion of a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous catheter on a partial task training simulator with no technical errors.
Study: NCT01087970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously, for maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously in combination therapy, for a maximum of 6 cycles.~After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously, for a maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously, for a maximum of 6 cycles
Study: NCT02636907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501 Autoinjector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501 Prefilled syringe
Study: NCT00631033

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Diazoxide
Study: NCT02799797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided long axis placement of adductor canal catheter
Description: The long axis of the ultrasound probe is placed parallel to the long axis of the adductor canal while scanning, and the catheter is placed along the long axis of the canal using an in-plane approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided short axis placement of adductor canal catheter
Description: The long axis of the ultrasound probe is placed vertical to the long axis of the adductor canal while scanning, and the catheter is placed along the short axis of the canal using an in-plane approach

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philip CX 50 Ultrasound Scanner
Description: The linear (C5-12) probe of Philip CX 50 Ultrasound Scanner is used for scanning

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philip CX 50 Ultrasound Scanner
Description: The linear (C5-12) probe of Philip CX 50 Ultrasound Scanner is used for scanning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAJUNK Contiplex S Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAJUNK Contiplex S Catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivocaine
Description: 0.2% ropivacaine 10ml is given as loading dose. Following that, 0.2% ropivacaine 5ml/h is given as maintenance dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivocaine
Description: 0.2% ropivacaine 10ml is given as loading dose. Following that, 0.2% ropivacaine 5ml/h is given as maintenance dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue sulfentanil given postoperatively as PICA
Description: bolus: 2mg, lock time: 10min, 1h limitation: 8mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rescue sulfentanil given postoperatively as PICA
Description: bolus: 2mg, lock time: 10min, 1h limitation: 8mg
Study: NCT04104568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSupport for dementia - European-Portuguese version
Description: iSupport for dementia, European-Portuguese version consists in an online self-help training and support program developed by the World Health Organization to to provide education, skills training and support to informal caregivers of people with dementia and culturally adapted to Portugal by the Institute of Biomedical Sciences Abel Salazar and CINTESIS. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques. The program comprises 23 lessons on dementia and caregiver support distributed by 5 modules: 'Introduction to dementia'; 'Being a carer'; 'Caring for me'; 'Providing everyday care' and 'Dealing with behavior changes'. The education plan can be personalized by the caregiver and each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-book (comparator)
Description: The e-book contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
Study: NCT01362725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation system
Description: An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
Study: NCT01658943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study: NCT02396875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling and exercise protocol pre and post CRT implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral blood sampling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral blood sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central blood sampling pre and post CRT implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling
Study: NCT03519828

Intervention type: OTHER
Intervention: No intervention has been conducted
Description: It is an observational study, and no intervention has been conducted

Intervention type: OTHER
Intervention: No intervention has been conducted
Description: It is an observational study, and no intervention has been conducted
Study: NCT04814745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal infusion
Description: morphine 150 mcg will be used by intrathecal administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infusion
Description: tramadol administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: bilateral transversus abdominis plane block by using ropivacaine 80 mg
Study: NCT04109222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose vaccine, 2019-2020 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study: NCT01909869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXCEL-Ⅱ
Description: A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions
Study: NCT01686542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI plus renal sympathetic modification
Description: CPVI plus renal denervation to reduce atrial arrhythmia recurrence.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI
Description: CPVI alone to reduce atrial arrhythmia recurrence.